CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6 enrolled
Drug / intervention
Argus IIdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05285618
NCT05285618N/ACompleted
CompareCT.gov

Predicting the Perceptual Experience of Argus II Retinal Prosthesis System Users

University of California, Santa Barbara·interventional·Posted Mar 17, 2022·Updated Jan 1, 2025

In Brief

A clinical study evaluating Argus II for Retinitis Pigmentosa. Completed, enrolled 6 participants across 3 sites.

Detailed Summary

This Basic Experimental Studies Involving Humans (BESH) study investigates phosphene perception and performance factors in blind participants implanted with the Argus II retinal prosthesis system. Using paired-electrode stimulation, we analyze how phosphene shape and number are influenced by neuroanatomical factors, stimulus parameters, and spatial offsets. Additionally, we examine the causes of high current thresholds and limited spatial resolution, which impede pattern vision in Argus II devices. This research aims to provide insights for optimizing stimulation strategies and improving retinal prosthesis design.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinitis Pigmentosa
CountriesUnited States
CollaboratorsJohns Hopkins University, University of Michigan, National Eye Institute (NEI)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 17, 2022
Enrollment StartJan 11, 2022
Primary CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.3 years ago

Interventions

Argus IIdevice

Participants used the Argus II retinal prosthesis system in both experiments to perform visual perception tasks.